SERPIND1

SERPIND1 (Heparin Cofactor II) is a secreted serine protease inhibitor belonging to a distinct structural subgroup of the serpin gene family, sharing its five-exon, four-intron architecture with alpha1-antitrypsin, alpha1-antichymotrypsin, and rat angiotensinogen (PMID:2841345). Productive secretion depends on correct folding at the reactive-center region: a Pro443Leu substitution at the P2 site impairs secretion, causing mutant molecules to associate intracellularly with the chaperone GRP78/BiP, be retained in the perinuclear region, and undergo intracellular degradation without affecting mRNA transcription, thereby producing type I congenital HC II deficiency (PMID:11204559). Beyond its canonical inhibitory role, SERPIND1 promotes malignant cell behavior in ovarian cancer—driving proliferation, migration, invasion, G1-to-S transition, and EMT while suppressing apoptosis—through activation of PI3K/AKT signaling, as overexpression phenotypes are reversed by the PI3K/AKT inhibitor LY294002 (PMID:31637210). The protease specificity, structural basis of inhibition, and physiological substrates of SERPIND1 have not been characterized in the available corpus.

1. 1988 Medium

   Establishing the gene's exon-intron architecture placed SERPIND1 within a defined serpin subgroup, framing it as a structurally classical serine protease inhibitor.

   Evidence Genomic clone analysis and exon-intron mapping with cross-family sequence comparison

   PMID:2841345

   Open questions at the time

   • Genomic structure does not establish the inhibitory mechanism or target protease
   • No protein structural or biochemical characterization at this stage
2. 2001 High

   Identifying a P2-site Pro443Leu mutation that triggers chaperone-mediated retention and degradation defined the molecular basis of type I HC II deficiency and showed that secretion depends on correct reactive-center folding.

   Evidence Site-directed mutagenesis with transfection in COS-1/CHO-K1, pulse-chase, co-immunoprecipitation with GRP78/BiP, immunohistochemistry, and Northern blot

   PMID:11204559

   Open questions at the time

   • Does not define the degradation pathway components beyond GRP78/BiP association
   • Does not characterize the protease-inhibitory activity of wild-type protein
   • Generalization to other deficiency-causing mutations not addressed
3. 2019 Medium

   Functional perturbation in ovarian cancer cells linked SERPIND1 to oncogenic phenotypes mediated by PI3K/AKT signaling, extending its role beyond protease inhibition.

   Evidence Knockdown and overexpression in ovarian cancer cell lines with phenotypic assays and LY294002 pharmacological rescue

   PMID:31637210

   Open questions at the time

   • Mechanism connecting SERPIND1 to PI3K/AKT phosphorylation is not defined
   • Single cancer-type, single-lab evidence
   • No in vivo validation reported
4. 2019 Low

   Promoter analysis nominated NFKB1 as an upstream transcriptional regulator of SERPIND1 expression.

   Evidence Transcription factor promoter binding assay reported within the cancer study

   PMID:31637210

   Open questions at the time

   • Single method inferred from abstract-level description without full methodological detail
   • Functional consequence of NFKB1 binding on SERPIND1 transcription not quantified
   • No demonstration of direct binding by orthogonal assay

• The target protease specificity, structural mechanism of inhibition, and physiological substrates of SERPIND1 remain unresolved in this corpus.
• No protease substrate or kinetic characterization
• No structural model of the reactive-center loop
• No in vivo physiological role established